HomeAbout

TL;DR CNBC


Novo Nordisk's diabetes drug Ozempic slashed the risk of kidney disease progression in trial - TL;DR CNBC

Novo Nordisk's diabetes drug Ozempic slashed the risk of kidney disease progression in trial

Publishing timestamp: 2024-03-05 12:14:49


Summary

Novo Nordisk's drug Ozempic showed positive results in reducing the risk of kidney disease progression and related health complications in diabetic patients, leading to potential expanded approval and treatment opportunities.


Sentiment: POSITIVE

Tickers: NVONOVO.B-DKLLY

Keywords: novo nordisk a/spharmaceuticalsbusinessbusiness newsbiotech and pharmaceuticalssciencebreaking newseli lilly and cohealth care industrybiotechnology

Source: https://www.cnbc.com/2024/03/05/novo-nordisk-ozempic-cuts-risk-of-kidney-disease-progression.html


Developed by Leo Phan